Warning: These 7 stocks are scheduled to report earnings

This is a must read. If you cannot see this email properly, please click [here]( --------------------------------------------------------------- Sponsor Message [Revolutionary Device Redefines Cancer Detection]( [Learn More Now - Before Anticipated FDA Approval in 2024]( --------------------------------------------------------------- March 1, 2024 (Earnings Report) From the desk of the Editor Dear Reader, We just identified several stocks that are expected to release earnings very soon. If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments. Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements. --------------------------------------------------------------- Sponsor Message [Detecting Cancer in 1.5 Seconds: Early Investment Opportunity]( Stanford engineer's lofty goal of revolutionizing cancer diagnostics is expected to come to fruition with FDA review in its final stages. With a history of taking companies public, including a $2 billion market cap NASDAQ company, this may be his biggest venture yet! With the ability to detect cancer's "molecular fingerprint" in just 1.5 seconds, it also offers far superior accuracy to current detection methods! [Learn more about how this could transform the multi-billion dollar diagnostic market.]( --------------------------------------------------------------- [Instil Bio, Inc.]( Symbol: [TIL]( Recent Price: $11.92 Average Analyst Price Target: $36.00 (202.01%) Market Cap: $77.53M Last Year's EPS: $-2.2 Consensus EPS Forecast: $-2.8 Expected Earnings Date: Mar 04, 2024 Recent Analyst Action: Mitchell Kapoor, analyst at H.C. Wainwright, reiterates coverage on [Instil Bio, Inc. (TIL)]( in the Healthcare sector with a Buy rating and a price target of $18 (1 month ago). [TipRanks.com]( also reports that [Instil Bio, Inc.]( currently has 2 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $36.00 . The target pricing ranges from a high forecast of $54 down to a low forecast of $18. [Instil Bio, Inc. (TIL)](’s last closing price was $11.92 which would put the average price target at 202.01% upside. Here are 3rd party ratings for [TIL](: - TipRanks.com: Buy - TradingView.com: Buy - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Buy, Top 31% (79 out of 251) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [#1 Stock for Energy Crisis (Buy Now for Just $8)]( the world suffers an oil shock… And gas prices rip higher… One tiny company could have the answer to the global energy crisis. It’s using AI to crack open the largest untapped energy source on the planet… 5X larger than the biggest oil field on Earth. [Act fast, this $8 stock could be moments away from appreciating considerably.]( --------------------------------------------------------------- [Ondas Holdings Inc.]( Symbol: [ONDS]( Recent Price: $1.27 Average Analyst Price Target: $2.50 (96.85%) Market Cap: $83.26M Last Year's EPS: $-0.18 Consensus EPS Forecast: $-0.16 Expected Earnings Date: Mar 04, 2024 Recent Analyst Action: Glenn G, analyst at Ladenburg Thalmann & Co., reiterates coverage on [Ondas Holdings Inc. (ONDS)]( in the Technology sector with a Buy rating and a price target of $3.5 (2 months ago). [TipRanks.com]( also reports that [Ondas Holdings Inc.]( currently has 3 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $2.50 . The target pricing ranges from a high forecast of $3.5 down to a low forecast of $2. [Ondas Holdings Inc. (ONDS)](’s last closing price was $1.27 which would put the average price target at 96.85% upside. Here are 3rd party ratings for [ONDS](: - TipRanks.com: Buy - TradingView.com: Sell - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: buy - Zacks.com: Hold, Bottom 8% (231 out of 251) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Is Your Money - and Privacy - at Risk?]( digital dollar could be a major threat to both your money and your personal privacy. See how it might impact your financial freedom and data security – and what you can do to protect both. Be informed, stay ahead. [Protect Your Financial Privacy Now]( --------------------------------------------------------------- [Cara Therapeutics, Inc.]( Symbol: [CARA]( Recent Price: $0.85 Average Analyst Price Target: $5.90 (594.12%) Market Cap: $46.32M Last Year's EPS: $-0.58 Consensus EPS Forecast: $-0.53 Expected Earnings Date: Mar 04, 2024 Recent Analyst Action: Sumant Kulkarni, analyst at Canaccord Genuity, reiterates coverage on [Cara Therapeutics, Inc. (CARA)]( in the Healthcare sector with a Buy rating and a price target of $11 (1 month ago). [TipRanks.com]( also reports that [Cara Therapeutics, Inc.]( currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $5.90 . The target pricing ranges from a high forecast of $5 down to a low forecast of $1. [Cara Therapeutics, Inc. (CARA)](’s last closing price was $0.85 which would put the average price target at 594.12% upside. Here are 3rd party ratings for [CARA](: - TipRanks.com: Buy - TradingView.com: Neutral - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: sell - Zacks.com: Hold, Top 31% (79 out of 251) [Click for chart >>]( -------------------------------------------------------------------------- [Ekso Bionics Holdings, Inc.]( Symbol: [EKSO]( Recent Price: $1.90 Average Analyst Price Target: $10.00 (426.32%) Market Cap: $33.85M Last Year's EPS: $-0.31 Consensus EPS Forecast: $-0.31 Expected Earnings Date: Mar 04, 2024 Recent Analyst Action: Swayampakula Ramakanth, analyst at H.C. Wainwright, reiterates coverage on [Ekso Bionics Holdings, Inc. (EKSO)]( in the Healthcare sector with a Buy rating and a price target of $10 (1 month ago). [TipRanks.com]( also reports that [Ekso Bionics Holdings, Inc.]( currently has 1 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $10.00 . The target pricing ranges from a high forecast of $10 down to a low forecast of $10. [Ekso Bionics Holdings, Inc. (EKSO)](’s last closing price was $1.90 which would put the average price target at 426.32% upside. Here are 3rd party ratings for [EKSO](: - TipRanks.com: Buy - TradingView.com: Sell - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: buy - Zacks.com: Buy, Top 33% (84 out of 251) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Fox Couldn't Air my #1 A.I. Pick - Get it Here.]( Wall Street Insider Marc Chaikin got invited onto Fox News to talk about A.I. - Here's what he couldn't say on television. [More here.]( --------------------------------------------------------------- [AnaptysBio, Inc.]( Symbol: [ANAB]( Recent Price: $25.53 Average Analyst Price Target: $49.80 (95.06%) Market Cap: $678.46M Last Year's EPS: $-1.5 Consensus EPS Forecast: $-1.72 Expected Earnings Date: Mar 04, 2024 Recent Analyst Action: Julian Harrison, analyst at BTIG, reiterates coverage on [AnaptysBio, Inc. (ANAB)]( in the Healthcare sector with a Buy rating and a price target of $55 (4 days ago). [TipRanks.com]( also reports that [AnaptysBio, Inc.]( currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $49.80 . The target pricing ranges from a high forecast of $80 down to a low forecast of $20. [AnaptysBio, Inc. (ANAB)](’s last closing price was $25.53 which would put the average price target at 95.06% upside. Here are 3rd party ratings for [ANAB](: - TipRanks.com: Buy - TradingView.com: Buy - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Hold, Top 31% (79 out of 251) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Game-Changing Cancer Tech Nears FDA Completion]( the world of tech advancements, a new player could outshine even AI. It's a revolutionary technology with the aim of transforming cancer detection. Imagine the leap from basic reading glasses to cutting-edge VR; that's the scale of innovation we're talking about. FDA review is in its final stages and it could become the gold standard before we know it. [Explore Investment Opportunities in This Market Disruptor]( --------------------------------------------------------------- And there you have it--- Stocks expected to release earnings soon... Sincerely, The Editor, DividendPress.com MarketInsidersPress.com Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. Content marked as "Ad," "Special" or "Sponsor" may be a third party advertisements where the advertiser is paying per click, per lead or per sale and are not endorsed or warranted by our staff or company. Sandpiper Marketing Group, LLC is also being compensated by Summit Publishing Group and Investing Trends up to three dollars per click and may exceed twelve thousand, five hundred dollars per week for placement of specific advertisements contained in this newsletter. Sandpiper Marketing Group, LLC and its principles do not own any of the stocks mentioned in this email or in the article that this email links to. Please see the disclaimer on the advertiser's website for additional information, including their relationship with any mentioned security. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. This newsletter may contain information regarding investment ideas and third-party ratings regarding specific securities. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. Sandpiper Marketing Group, LLC nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Sandpiper Marketing Group, LLC to buy or sell any security. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. [If you are not a human, click here.]( By opening this email or clicking any links contained, you are reconfirming your opt-in status. You can unsubscribe at any time by clicking the link below in the footer. This is part of your free subscription to MarketInsidersPress.com MarketInsidersPress.com part of Sandpiper Marketing Group, LLC 165 Lockerbie Lane | Mooresville NC | 28115 MarketInsidersPress.com part of Sandpiper Marketing Group, LLC | 1519 Mecklenburg Hwy | Unit 4 | Mount Mourne | NC | 28123 | United States | 877-411-9808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software